MedPath

Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients

Phase 3
Completed
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Device: Genuair® (Almirall S.A.)
Device: HandiHaler® (Boehringer Ingelheim's)
Registration Number
NCT01385696
Lead Sponsor
Almirall, S.A.
Brief Summary

Preference study: Genuair vs HandiHaler inhalers in COPD patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • Adult male or female patients aged ≥ 40 with stable COPD
  • Naïve patients to the use of study inhalers
  • Patients agreeing on participating and signing the Informed Consent Form
Read More
Exclusion Criteria
  • Patients with other clinically significant disease, particularly body malformations or diseases affecting coordination and/or motor system
  • Patients unable to read product package instructions and answer patient reported questionnaires
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
group AGenuair® (Almirall S.A.)Genuair first, HandiHaler second
group BGenuair® (Almirall S.A.)HandiHaler first, Genuair second
group AHandiHaler® (Boehringer Ingelheim's)Genuair first, HandiHaler second
group BHandiHaler® (Boehringer Ingelheim's)HandiHaler first, Genuair second
Primary Outcome Measures
NameTimeMethod
Percentage of Patients Who Prefer Genuair Device Versus Handihaler Device at Visit 214 days

Patients will be asked to answer which device they prefer after 2 weeks of daily practice (visit 2)

Secondary Outcome Measures
NameTimeMethod
Mean Overall Satisfaction With Genuair and Handihaler at Visit 214 days

The patient will be asked to rate the overall satisfaction with each device using a Likert-type scale (from 1 \[very dissatisfied\] to 5 \[very satisfied\]) after 2 weeks of daily practice (visit 2)

Percentage of Patients Making at Least 1 Critical Error Using the Genuair and Handihaler Devices at Visit 214 days

The correct use of devices will be assessed measuring the errors made by patients when using each device after 2 weeks of daily practice (visit 2).

Critical error is defined as the one that compromise the potential benefit of the treatment such as those that impede drug deposition in the lungs or delivery of sufficient dose.

Trial Locations

Locations (4)

Almirall investigative site 2

🇳🇱

Zutphen, Netherlands

Almirall investigative site 1

🇳🇱

Enschede, Netherlands

Almirall investigative site 5

🇩🇪

Koblenz, Germany

Almirall investigative site 3

🇩🇪

Bonn, Germany

© Copyright 2025. All Rights Reserved by MedPath